Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
I References
References
Abounader, R, Montgomery, R, Dietz, H., Laterra, J. (2004) Design and
expression of chimeric U1/ribozyme transgenes. Methods Molecular Biology,
252 :209-219.
Adaichi, A., Glendelman, H.E., Koenig, S., Folks, T., Willey, R, Rabsom, A.,
and Martin, M. (1986). Production of acquired immunodeficiency syndrome
associated retrovirus in human and nonhuman cells transfected with an
infectious molecular clone. Journal of Virology, 59: 284-291.
Akkina, R, Banerjea, A., Bai, J., Anderson, J., Li, M. J. & Rossi, J. J. (2003) Si
RNAs, ribozymes, and RNA decoys in modeling stem cell based gene
therapy for HIV/AIDS. Anticancer Research, 23:1997-2005.
Amado, RG., Mitsuyasu, RT., Symonds, G. (1999) A phase I trial of
autologous CD34p hematopoietic progenitor cells transduced with an anti
HIV ribozyme. Human Gene Therapy,10 :2255- 2270.
Andersen, A.A. and Collins,RA. (2000) Rearrangement of a stable RNA
secondary structure during VS ribozyme catalysis. Molecular Cell, 5: 469-478.
Andersen, J.L., DeHart, J.L., Zimmerman, E.S., Ardon, 0., Kim, B., Jacquot, G.
(2006) HIV-1 Vpr-Induced Apoptosis Is Cell Cycle Dependent and Requires
Bax but Not ANT. PLoS Pathogens, 2(12): e127.
Andersen, J.L., Le Rouzic, E., Planelles, V. (2008) HIV-1 Vpr: Mechanisms of
G2 arrest and apoptosis. Experimental and Molecular Pathology, 85: 2-10.
Anderson, J. and Akkina, R (2005). HIV-1 resistance conferred by siRNA
cosuppression of CXCR4 and CCR5 coreceptors by a bi-specific lentiviral
vector. AIDS Research Therapy, 2: 1-12.
149 I P age
I References
Anderson J, Banerjea A, Akkina R(2003a) Bispecific short hairpin siRNA
constructs targeted to CD4, CXCR4, and CCR5 confer HIV -1 resistance.
Oligonucleotides, 13(5):303-312.
Anderson, J., Banerjea, A., and Akkina, R (2003b). Suppression of HIV-l
infection by a stem loop structured anti-CXCR4 siRNA. AIDS Research and
Human Retroviruses, 19: 699-706.
Angers, S. (2006). Molecular architecture and assembly of the DDBI-CUL4A
ubiquitin ligase machinery. Nature, 443: 590-593.
Appaiahgari, M.B., Vrati, S. (2007) DNAzyme-mediated inhibition of Japanese
encephalitis virus replication in mouse brain. Molecular Therapy,15(9):1593-
1599.
Arunagiri, c., Macreadie, I., Hewish, D. and Azad, A. (1997) A C-terminal
domain of HIV-l accessory protein Vpr is involved in penetration,
mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes.
Apoptosis, 2: 69-76.
Bahner, I., Kearns, K., Haq, Q.-L., Smogorzewska, E. M., and Kohn, D. B.
(1996). Transduction of human CD34+ hematopoetic progenitor cells by a
retroviral vector expressing an RRE decoy inhibits human immunodeficiency
virus type I replication in myelomonocytic cells produced in long term
culture. Journal of Virology, 70: 4352-4360.
Bai, J., Gorantala, S., Banda, N., Cagnon, L., Rossi, J., and Akkina R (2002).
Characterisation of anti-CCR5 ribozyme transduced CD34+ hematopoetic
progenitor cells in vitro and in a SCID-hu mouse model in vivo. Molecular
Therapy, 1: 244-254.
150 I P age
I References
Bai, J., Rossi, J., and Akkina, R(200l). Multivalent anti CCR5 ribozymes for
stem cell based HIV type I gene therapy. AIDS Research and Human
Retroviruses, 17: 385-399.
Banerjea, A.C. (2008) Host genes that affect AIDS/HIV progression in India
and novel gene therapeutic approaches against HIV. Indian Journal of
Biochemistry and Biophysics, 45: 141-148.
Banerjea, A.C., Chakraborti, S., Unwalla, H., Goila, R, Shrabani, B., Dash,
B.c., Sriram, B., Paramasivam, N., and Vishwanathan, S. (2005). Potential
therapeutic application of DNA enzymes and siRNAs against viral and
cellular genes. In: Synthetic Nucleic Acids as Inhibitors of Gene Expression:
Mechanisms, Applications, and Therapeutic Implications. L.M. Khachigian,
ed. (CRC Press, Boca Raton, FL), pp. 115-134.
Bano, AS., Gupta, N., Sood, V., Banerjea, A.C. (2007) Vpr from HIV-1
subtypes Band C exhibit significant differences in their ability to transactivate
LTR-mediated gene expression and also in their ability to promote apoptotic
DNA ladder formation. AIDS, 21: 1832-1834.
Bao, P., Wu, Q-J., Yin, P., Jiang, Y., Wang, X., Xie, M-H., Sun, T., Huang, L.,
Mo, D.D., Zhang, Y. (2008) Coordination of two sequential ester-transfer
reactions: exogenous guanosine binding promotes the subsequent G binding
to a group I intron. Nucleic Acids Research, 36(21):6934-6943.
Barre-Sinoussi, F., Chermann, J. c., Rey, F., Nugeyre, M. T., Chamaret, S.,
Gruest, J. (1983). Isolation of a T-lymphotropic retrovirus from a patient at
risk for acquired immune deficiency syndrome (AIDS). Science, 220: 868-871.
Bartz, S.R, Rogel, M.E., Emerman, M. (1996) Human immunodeficiency virus
type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a
151 I P age
I References
mechanism which differs from DNA damage checkpoint control. Journal of
Virology, 70(4) :2324-2331.
Basu, S., Sriram, S., Goila, Rand Banerjea, A. C. (2000).Targeted cleavage of
HIV-1 coreceptor - CXCR-4 by RNA cleaving DNA-enzyme: Inhibition of
coreceptor function. Antiviral Research, 46: 125-134.
Baum, D.A. and Silverman, S.K(2008) Deoxyribozymes: useful DNA catalysts
in vitro and in vivo. Cellular and Molecular Life Science, 65: 2156 - 2174.
Beigelman, L., McSwiggen,J.A., Draper,KG., Gonzalez,C., Jensen,K,
Karpeisky,A.M., Modak,A.5., Matulic-AdamicJ., DiRenzo, A. B., Haeberli, P.,
Sweedler,D., Tracz, D., Grimm,S., Wincott,F.E.,Thackray,V.G. and Usman,N.
(1995)Chemical Modification of Hammerhead Ribozymes. Journal of
biological chemistry,270( 43): 25702-25708.
Belzile, J.P. (2007). HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4A
(VPRBP) E3 ubiquitin ligase. PLoS Pathogen, 3(7): 882-894.
Berger, E. A., Murphy, P. M. and Farber, J. M. (1999) Chemokine receptorsas
HIV -1 coreceptor: Roles in viral entry, tropism, and disease. Annual Review
of Immunology, 17: 657-700.
Berson, J.F., Long, D., Doranz, B.J., Rucker, L Jirik, F.R, Doms, RW. (1996) A
seven-transmembrane domain receptor involved in fusion and entry of T -cell
tropic human immunodeficiency virus type 1 strains. Journal of Virology, 70:
6288-95.
Bhanja, P., Sengupta, S., Banerjee, B., Sarkar, K, Jana, S., Chakrabarti, S.
(2007) Detection of intersubtype recombinants with respect to env and nef
genes of HIV-1 among female sex workers in Calcutta, India. Virus Research,
130: 310-314.
152 I P age
I References
Bhindi, R, Fahmy, RG., Lowe, H.C, Chesterman, CN., Dass, CR, Cairns,
M.J., Saravolac, E.G., Sun, L.Q. and Khachigian, L.M. (2007) Brothers in Arms
DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small
Molecule Nucleic Acid-Based Gene-Silencing Strategies. The American
Journal of Pathology,l71 (4): 1079-1089.
Bikandou, B., Takehisa, J., et aI., (2000) Genetic Subtypes of HIV Type 1 in
Republic of Congo. AIDS Research and Human Retroviruses, 16(7): 613-619.
Blackard, J.T., Renjifo, B., Fawzi, W., Hertzmark, E., Msamanga, G.,
Mwakagile, D., et aI., (2001) HIV-l LTR subtype and perinatal transmission.
Virology, 287 : 261-265.
Bleul, CC, Farzan, M., Choe, H., Parolin, C, Clark-Lewis, I., Sodroski, J.
(1996) The lymphocyte chemoattractant SDF-l is a ligand for LESTR/ fusin
and blocks HIV-l entry. Nature, 382: 829-833.
Bobkov, A.F., Kazennova, E.V., Sukhanova, A.L., Bobkova, M.R, Pokrovsky,
V.V., Zeman, V.V., Kovtunenko, N.G., Erasilova, LB. (2004) An HIV type 1
subtype A outbreak among injecting drug users in Kazakhstan.AIDS Research
and Human Retroviruses, 20(10):1134-1136.
Bogerd, H.P., Wiegand, H.L., Hulme, A.E., Garcia-Perez, J.L., O'Shea, K.S.,
Moran, J.V., Cullen, B.R(2006). Cellular inhibitors of long interspersed
element 1 and Alu retrotransposition. Proceedings of National Academy of
Sciences U. S. A,103: 8780-8785.
BouHamdan, M. (2001) Inhibition of HIV -1 infection by down-regulation of
the CXCR4 co-receptor using an intracellular single chain variable fragment
against CXCR4. Gene Therapy, 8: 408-418.
153 I P age
I References
Bourbigot, S. (2005). The C-terminal domain of the HIV-1 regulatory protein
VPR adopts an anti parallel dime ric structure in solution via its leu cine-zip per
like domain. Biochemical Journal, 387: 333-341.
Breaker, RR and Joyce, G.F. (1994) A DNA enzyme that cleaves RNA.
Chemical Biology, 1(4): 223-229.
Bukrinsky, M.I., Haffar, O.K.(1998) HIV-1 nuclear import: matrix protein is
back on center stage, this time together with Vpr. Molecular Medicine, 4:138-
143.
Cairns, M.J., Hopkins, T.M., Witherington, c., Wang, L., and Sun, L.Q. (1999).
Target site selection for an RNA-cleaving catalytic DNA. Nature
Biotechnology, 17: 480-486.
Campbell, T. B., McDonald, C. K. and Hagen, M.(1997a) The effect of
structure in a large target RNA on ribozyme cleavage efficiency, Nucleic
Acids Research, 25 (24), 4985.
Campbell, T.B., McDonald, c.K. and Hagen, M. (1997b) The effect of structure
in a large target RNA on ribozyme cleavage efficiency, Nucleic Acids
Research, 25 (24): 4985-4993.
Cassol, S., Weniger, B.G., Babu, P.G., Salminen, M.O., Zheng, X., Htoon, M.T.,
Delaney, A., O'Shaughnessy, M. and Ou, c.y. (1996) Detection of HIV type 1
env subtypes A, B, C, and E in Asia using dried blood spots: a new
surveillance tool for molecular epidemiology. AIDS Research and Human
Retroviruses, 12: 1435-1441.
Carl Woese, 1967 The Genetic Code. New York: Harper and Row
Carmi, N. and Breaker, RR (2001) Characterization of a DNA-cleaving
deoxyribozyme. Bioorganic Medicinal Chemistry, 9: 2589-2600.
154 I P age
- --- - - -----------------------
I References
Cech, T.R (1993) The efficiency and versatility of catalytic RNA: implications
for an RNA world. Gene, 135: 33-36.
Cech, T.R, Zaug, A.J. and Grabowski, P.J. (1981) In vitro splicing of the
ribosomal RNA precursor of tetrahymena :involvement of a guanosine
nucleotide in the excision of the intervening sequence. Cell 27: 487-496.
Chakraborti, S. and Banerjea, A.C (2003a). Identification of cleavage sites in
the HIV-l TAR RNA by 10- 23 and 8-17 catalytic motif containing DNA
enzymes. Biomacromolecules, 4: 568-571.
Chakraborti, S. and Banerjea, A.C (2003b). Inhibition of HIV -1 replication by
10-23 catalytic motif containing DNA-enzymes targeted against HIV-l TAR
element: potential effectiveness against all HIV -1 isolates. Molecular Therapy,
7: 817-826.
Chan, D.C, Fass, D., Berger, J.M., Kim, P.s.(1997) Core structure of gp41 from
the HIV envelope glycoprotein. Cell, 89(2):263-273.
Chaudhry, A., Verghese, D.A., Das, S.R, Jameel, S., George, A., Bal, V.,
Mayor, S., Rath, S. (2009). HIV-l Nef Promotes Endocytosis of Cell Surface
MHC Class II Molecules via a Constitutive Pathway. Journal of Immunology,
183(4): 2415-2424.
Chen, J., Dang, Q., Unutmaz, D., Pathak, V.K., Maldarelli, F., Powell, D. (2005)
Mechanisms of nonrandom human immunodeficiency virus type 1 infection
and double infection: preference in virus entry is important but is not the sole
factor. Journal of Virology, 79: 4140-4149.
Chiu, Y.L., Rana, T.M.(2003) siRNA function in RNAi: a chemical
modification analysis. RNA, 9:1034-1048.
155 I P age
I References
Chun, T.W., Fauci, A.s.(1999) Latent reservoirs of HIV: obstacles to the
eradication of virus. Proceedings of National Academy of Sciences USA, 96:
10958-10961.
Clavel, F., Guetard, D., Brun-Vezinet, F., Chamaret, S., Rey, M.A., Santos
Ferreira, M.O., Laurent, A.G., Dauguet, C, Katlama, C, Rouzioux, C(1986)
Isolation of a new Human retrovirus from West African patients with AIDS.
Science, 233:343-346.
Coburn, G.A. and Cullen, B.R(2002) Potent and specific inhibition of human
immunodeficiency virus type 1 replication by RNA interference. Journal of
Virology, 76: 9225-9231.
Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, RC, Lusso, P.
(1995) Identification of RANTES, MIP-1a, and MIP-1b as the major HIV
suppressive factors produced by CD8+ T cells. Science, 270:1811-1815.
Cocchi, F., DeVico, A.L., Garzino-Demo, A., Cara, A., Gallo, RC, Lusso, P.
(1996) The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for
chemokine-mediated blockade of infection. Nature Medicine, 2: 1244-1247.
Cochrane, J.C, Lipchock, S.V. and Strobe, S.A. (2007) Structural Investigation
of the GlmS Ribozyme Bound to Its Catalytic Cofactor. Chemistry & Biology,
14(1): 97-105.
Coffin, J., Haase, A., Levy, J.A, Montagnier, L., Oroszlan, S., Teich, N.(1986)
Human immunodeficiency viruses [letter]. Science, 232: 697.
Cohen, E.A., Dehni, G., Sodroski, J.G., Haseltine, W.A.(1990) Human
immunodeficiency virus vpr product is a virion-associated regulatory protein.
Journal of Virology, 64: 3097-3099.
156 I P age
I References
Combadiere, c., Ahuja, S.K., Tiffany, H.L., Murphy, P.M.(1996) Cloning and
functional expression of CC CKR5, a human monocyte CC chemokine
receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. Journal of
Leukocyte Biology, 60:147-152.
Cruz, RP.G., Withers, J.B., Li, Y. (2004) Dinucleotide junction cleavage
versatility of 8-17 deoxyribozyme. Chemical. Biology, 11: 57-67.
Cullen, B.R (1995). Regulation of HIV gene expression. AIDS, 9: 19-32.
Cullen, B.R (2006). Role and mechanism of action of the APOBEC3 family of
antiretroviral resistance factors. Journal of Virology, 80: 1067-1076.
Dalgleish, A.G., Beverley, P.c., Clapham, P.R, Crawford, D.H., Greaves, M.F.,
Weiss, RA.(1984) The CD4 (T4) antigen is an essential component of the
receptor for the AIDS retrovirus. Nature, 312: 763-767.
Danial, N.N., Korsmeyer, S.J. (2004). Cell death: critical control points. Cell,
116: 205-219.
Dash, B. C. and Banerjea, A. C. (2004) Sequence specific cleavage activities of
DNA-enzymes targeted against HIV-1 Gag and Nef regions.
Oligonucleotides, 14: 41-47.
Davidson, A., Leeper, T.C., Athanassiou, Z., Patora-Komisarska, K., Karn, J.,
Robinson, J.A., Varani, G. (2009) Simultaneous recognition of HIV-1 TAR
RNA bulge and loop sequences by cyclic peptide mimics of Tat protein.
Proceedings of National Academy of Sciences USA, 106(29):11931-11936.
de Noronha, C.M. (2001). Dynamic disruptions in nuclear envelope
architecture and integrity induced by HIV-1 Vpr. Science, 294: 1105-1108.
Deniaud, A., Brenner, c., Kroemer, G. (2004) Mitochondrial membrane
permeabilisation by HIV-1 Vpr. Mitochondrion, 4: 223-233.
157 I P age
I References
Deshpande A, Pinson PR, Deshmukh R, Faure M, Jauvin V, Garrigue I, et al.
Molecular characterization of HIV type 1 isolates from untreated patients of
Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS
Res Hum Retroviruses 2004; 20:1032-1035.
Deshpande, A., Jauvin, V., Pinson, P., Jeannot, A.C. and Fleury, H.J. (2009)
Phylogenetic analysis of HIV -1 reverse transcriptase sequences from 382
patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008.
AIDS Research and Human Retroviruses, 25: 633-635
Doms, R.W.(2000) Beyond receptor expression: the influence of receptor
conformation, density, and affinity in HIV -1 infection. Virology, 276: 229-237.
Donze,G., and Picard, D. (2002). RNA interference in mammalian cells using
siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Research,
30(10): e46.
Doranz, B.J., Berson, J.F., Rucker, J., Doms, R.W. (1997)Chemokine receptors
as fusion cofactors for human immunodeficiency virus type 1 (HIV-l).
Immunological Research,16: 15-28.
Dragic, T., Charneau, P., Clavel, F., Alizon, M.(1992) Complementation of
murine cells for human immunodeficiency virus envelope/CD4- mediated
fusion in human/murine heterokaryons. Journal of Virology, 66: 4794-4802.
Egelhofer, M. (2004) Inhibition of human immunodeficiency virus type 1
entry in cells expressing gp41-derived peptides. Journal of Virology, 78: 568-
575.
Evans, D., Marquez, S.M. and Pace, N.R. (2006) RNase P: an interface of RNA
and Protein world. TRENDS in Biochemical Sciences, 31(6): 333-341.
158 I P age
I References
Fahmy, RG., Dass, CR, Sun, L.Q., Chesterman, CN., Khachigian, L.M. (2003)
Transcription factor Egr-1 supports FGF-dependent angiogenesis during
neovascularization and tumor growth. Nature Medicine, 9:1026-1032.
Fahmy, R, Waldman, A., Zhang, G., Mitchell, A., Tedla, N., Cai, H.,
Chesterman, CN., Geczy, CR, Perry, M.A., Khachigian, L.M. (2006)
Suppression of vascular permeability and inflammation by targeting of the
transcription factor c-Jun. Nature Biotechnology, 24: 856-863.
Fan, J., Negroni, M., Robertson, D.L. (2007) The distribution of HIV-1
recombination breakpoints. Infection, Genetics and Evolution, 7: 717-723.
Fedor, M. J. (1999) Tertiary Structure Stabilization Promotes Hairpin
Ribozyme Ligation. Biochemistry, 38: 11040-11050.
Fedor,M.J.(2009)Comparative Enzymology and Structural Biology of RNA
Self-Cleavage, Annual Review of Biophysics, 38: 271-299.
Fedoruk-Wyszomirska, A., Giel-Pietraszuk, M., Wyszko, E., Szymanski, M.
Ciesiolka, J., Barciszewska, M.Z., Barciszewski, J.(2008)The mechanism of
acidic hydrolysis of esters explains the HDV ribozyme activity, Molecular
Biology Reports, 36(7):1647-1650.
Fedoruk-Wyszomirska, A., Szymanski, M., Wyszko, E., Barciszewska, M.Z.,
Barciszewski, J. (2009) Highly active low magnesium hammerhead ribozyme.
J Biochem.145(4):451-459.
Feng, Y., Broder, CC, Kennedy, P.E., Berger, E.A. (1996) HIV-1 entry cofactor:
functional cDNA cloning of a seven-transmembrane, G proteincoupled
receptor. Science, 272:872-877.
Feng, Y., Leavitt, M., Tritz, R, Duarte E., Kang, D., Mamounas, M., Gilles, P.,
Wong-Staal, F., Kennedy, S., Merson, J., Yu, M., and Barber, J. R (2000).
159 I P age
I References
Inhibition of CCR5 dependent HIV -1 infection by hairpin ribozyme gene
therapy against CC-chemokine receptor 5. Virology, 276: 271-278.
Ferre-D'Amare, A.R (2004) The hairpin ribozyme. Biopolymers, 73: 71-78.
Ferre-D'Amare, A.R, Zhou, K, Doudna, J.A. (1998) Crystal structure of
Hepatitis delta virus, Nature, 395 (6702): 567-574.
Fire, A., Xu,S., Montgomery, M., Kostas,S., Driver,S., Mello, C (1998) Potent
and specific genetic interference by double-stranded RNA in Caenorhabditis
elegans. Nature, 391(6669): 806-811.
Forster, A. C, and Altman, S. (1990) External guide sequences for an RNA
enzyme. Science, 249: 783-786.
Forster, A.C and Symons, RH. ,(1987) self cleaving of virusoid RNA is
performed by the proposed 55- nucleotide active site, cell, 50: 9-16
Fukushima, A., Fukuda, N., Lai, Y., Ueno, T., Moriyama, M., Taguchi, F.,
Iguchi, A., Shimizu, K, Kuroda, K(2009) Development of a chimeric DNA
RNA hammerhead ribozyme targeting SARS virus.lntervirology. 52(2):92-99.
Gadkari, D.A., Moore, D., Sheppard, H.W., Kulkarni, 5.5., Mehendale, S.M.
and Bollinger, RG. (1998) Transmission of genetically diverse strains of HIV-1
in Pune, India. Indian Journal of Medical Research, 107: 1-9.
Gallo, RC, Salahuddin, S.Z., Popovic, M., Shearer, G.M., Kaplan, M., Haynes,
B.F.(1984). Frequent detection and isolation of cytopathic retroviruses (HTLV
III) from patient with AIDS and at a risk for AIDS. Science, 224: 500-503.
Ganeshan, 5., Dickover, R E., Korber, B. T., Bryson, V. J. & Wolinsky, S. M.
(1997). Human immunodeficiency virus type 1 genetic evolution in children
with different rates of development of disease. Journal of Virology, 71: 663-
677.
160 I P age
I References
Garzino-Demo, A., DeVico, A.L., Cocchi, F., Gallo, RC ~-chemokines and
protection from HIV type 1 disease. AIDS Research and Human Retroviruses,
14:S177-184.
Gibbs, J.S., Lackner, A.A., Lang, S.M., Simon, M.A.,Sehgal, P.K., Daniel, M.D.,
and Desrosiers, RC(1995). Progression to AIDS in the absence of a gene for
Vpr or Vpx. Journal of Virology, 69: 2378-2383.
Goh, W.C, Rogel, M.E., Kinsey, CM., Michael, S.F., Fultz, P.N., Nowak, M.A.,
Hahn, B.H., Emerman, M.(1998) HIV-1 Vpr increases viral expression by
manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.
Nature Medicine, 4(1): 65-71.
Goila, R, Banerjea, A. C (1998) Sequence specific cleavage of the HIV-1
coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme:
inhibition of the coreceptor function by DNA-enzyme. FEBBS Letter, 436
(2):233-238.
Goila, Rand Banerjea, A.C (2001) Inhibition of hepatitis B virus X gene
expression by novel DNA enzymes. Biochemical Journal, 353 (3): 701-708.
Goila-Gaur, R and Strebel, K.(2008) HIV-1 Vif, APOBEC, and Intrinsic
Immunity. Retrovirology, 5: 51-66.
Goodchild, J. (1992) Enhancement of ribozyme catalytic activity by a
contiguous oligonucleotide (facilitator) and by 2' -O-methylation. Nucleic
Acids Research, 20: 4607-4612.
Gupta, N., Bano, AS., Sharma, Y., Banerjea, A.C (2008) Potent knockdown of
the X RNA of hepatitis B by a novel chimeric siRNA-ribozyme construct and
modulation of intracellular target RNA by selectively disabled
mutants. Oligonucleotides. 18(3 ) :225-233.
161 I P age
I References
Gupta, N., Bano,A.S., Sharma, Y.,Sood, V. and Banerjea, A.C(2007). Potent
intracellular knock down of hepatitis B virus X RNA by catalytic hammerhead
ribozymes or DNA-enzymes with antisense DNA-oligonucleotides or 10-23
DNA-enzymes that powerfully augment in vitro sequence specific cleavage
activities. The Open Biotechnology Journal, 1: 81-92.
Haase, A.T.(1986) pathogenesis of lentivirus infections. Nature, 322:131-136.
Hampel, A. and Tritz, R (1989) RNA catalytic properties of the minimum (-) s
TRSV sequence. Biochemistry, 28: 4929-4933.
He, Z., Zhang, W., Chen, G., Xu, Rand Yu, X. F. (2008). Characterization of
Conserved Motifs in HIV-1 Vif Required for APOBEC3G and APOBEC3F
Interaction. Journal of Molecular Biology, 381:1000-1011.
Hendry, P., Mc Call, M.J., Santiago, F.5. and Jennings, P.A. (1995) In vitro
activity of minimized hammerhead ribozymes. Nucleic acid research, 23:
3922-3927.
Herring, B.L., Ge, Y.C, Wang, B., Ratnamohan, M., Zheng, F., Cunningham,
A.L., Saksena, N.K. and Dwyer, D.E. (2003) Segregation of Human
Immunodeficiency Virus Type 1 Subtypes by Risk Factor in Australia. Journal
of Clinical Microbiology, 41(10): 4600-4604.
Higa, L. A. and Zhang, H. (2007) Stealing the spotlight: CUL4-DDB1
ubiquitin ligase docks WD40-repeat proteins to destroy. Cell Division, 2: 5-14.
Hirsch, V.M., Sharkey, M.E., Brown,CR, Brichacek, B., Goldstein, S.,
Wakefield, J., Byrum, R, Elkins, W.R, Hahn, B.H., Lifson, J.D., and Stevenson,
M. (1998). Vpx is required for dissemination and pathogenesis of SIV (SM):
evidence of macrophage-dependent viral amplification. Nature Medicine, 4:
1401-1408.
162 I P age
I References
Hiscott, J., Kwon, H., Genin, P. (2001). "Hostile takeovers: viral appropriation Ii)
of the NF-kappaB pathway". Journal of Clinical Investigation, 107 (2): 143-
151.
Hogan, T.H., Nonnemacher, M.R, Krebs, F.C, Henderson, A., Wigdahl,
B.(2003) HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and
adjacent regions is sequence-specific. Biomedical Pharmacotherapy, 57: 41-48.
Horn, S., Schwenzer, B.(1999) Oligonucleotide facilitators enhance the
catalytic activity of RNA-cleaving DNA enzymes. Antisense Nucleic Acid
Drug Development, 9: 465-472.
Hornung, V., Guenthner-Biller, M., Bourquin, C, Ablasser, A., Schlee, M.,
Vematsu, S., Noronha,A., Manoharan, M., Akira, S., de Fougerolles, A.,
Endres, S.,Hartmann, G.(200S) Sequence-specific potent induction of IFN
alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.
Nature Medicine, 11: 263-270.
Huang, Y., Paxton, W.A., Wolinsky, S.M., Neumann, A.V., Zhang, 1., He, T.,
Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D.,
Dragon, E., Landau, N.R, Phair, J., Ho, D.D., Koup, RA.(1996) The role of a
mutant CCRS allele in HIV -1 transmission and disease progression. Nature
Medicine, 2(11):1240-1243.
Husain S, Goila R, Shahi Sand Banerjea AC(1998) First report of a healthy
Indian heterozygous for D32 mutant of HIV -1 coreceptor-CCRS gene. Gene,
207: 141-147.
Isaka, Y., Nakamura, H., Mizui, M., Takabatake, Y., Horio, M., Kawachi, H.,
Shimizu, F., Imai, E., Hori, M. (2004) DNAzyme for TGF-~ suppressed
extracellular matrix accumulation in experimental glomerulonephritis.
Kidney International, 66:586-590.
163 I P age
I References
Iversen, P.O., Nicolaysen, G., Sioud, M. (2001) DNA enzyme targeting
TNFalpha mRNA improves hemodynamic performance in rats with
postinfarctionheart failure. American Journal of Physiology, 281: H2211-
H2217.
Jacotot, E., Ravagnan, L., Loeffler, M., Ferri, KF., Vieira, H.L., Zamzami, N.
(2000) The HIV -1 viral protein R induces apoptosis via a direct effect on the
mitochondrial permeability transition pore.
Medicine, 191: 33-46.
Journal of Experimental
Jacque, J.M., Triques, K, Stevenson, M.(2002) Modulation of HIV-1 replication
by RNA interference. Nature, 418: 435-438.
Jameel, 5., Zafrulla, M., Ahmad, M., Kapoor, G.P. and Sehgal, S. (1995) A
genetic analysis of HIV -1 from Punjab, India reveals the presence of multiple
variants. AIDS, 9: 685-690.
Jankowsky, E.B., Schwenzer, B. (1996) Oligonucleotide facilitators may inhibit
or activate a hammerhead ribozyme. Nucleic Acids Research, 24: 423-429.
Jensen, M.A., 't Wout, A.B.(2003) Predicting HIV-1 coreceptor usage with
sequence analysis. AIDS Review, 5:104-112.
Jere, A., Tripathy, 5., Agnihotri, K, Jadhav, 5., Paranjape, R. (2004) Genetic
analysis of Indian HIV -1 nef subtyping, variability and implications. Microbes
and Infection, 6: 279-289.
Jian, H., and Zhao, L.J. (2003). Pro-apoptotic activity of HIV-1 auxillary
regulatory protein Vpr is subtype-dependent and potentially enhanced by
nonconservative changes of the leucine residue at position 64. Journal of
Biological Chemistry, 278: 44326-44330.
164 I P age
I References
Joyce, G.F. (2004) Directed evolution of nucleic acid enzymes. Annual Review
of Biochemistry, 73: 791-836.
Karni, 0., Friedler, A., Zakai, N., Gilon, c., Loyter, A.(1998) A peptide derived
from the N-terminal region of HIV-1 Vpr promotes nuclear import in
permeabilized cells: elucidation of the NLS region of the Vpr. FEBS Letter,
429:421-425.
Khachigian, L.M., Fahmy, R.G., Zhang, G., Bobryshev, Y.V., Kaniaros, A.
(2002) c-Jun regulates vascular smooth muscle cell growth and neointima
formation after arterial injury: inhibition by a novel DNAzyme targeting c
Jun. Journal of Biological Chemistry, 277: 22985-22991.
Kim, D. H. and Rossi, J. J. (2007). Strategies for silencing human disease using
RNA interference. Nature review Genetics, 8: 173-184
Kino, T., Gragerov, A., Slobodskaya, 0., Tsopanomichalou, M., Chrousos,
G.P., Pavlakis, G.N.(2002) Human immunodeficiency virus type 1 (HIV-1)
accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid
responsive promoters by binding directly to p300/CBP coactivators. Journal of
Virology, 76(19): 9724-9734.
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, l, Guetard, D.,
Hercend, T.(1984)T-lymphocyte T4 molecule behaves as the receptor for
human retrovirus LA V. Nature, 312:767-768.
Konopka K, Diizgiine~ N, Rossi J, Lee NS.(1998) Receptor ligand-facilitated
cationic liposome delivery of anti-HIV -1 Rev-binding aptamer and ribozyme
DNAs.J Drug Target.5(4):247-259.
Kostrikis, L.G., Huang, Y., Moore, J.P., Wolinsky, S.M., Zhang, L.Q., Guo, Y.,
Deutsch, L., Phair, J., Neumann, A.D., Ho, D.D. (1998). A chemokine receptor
165 I P age
I References
CCR2 allele delays HIV -1 disease progression and is associated with a CCR5
promoter mutation. Nature Medicine, 4:350-353.
Kraus, G., Geffin, R, Spruill, G., Young, A.K., Seivright, R, Cardona, D.,
Burzawa, I., Hnatyszyn, H.J. (2002) Cross-clade inhibition of HIV-1 replication
and cytopathology by using RNase P-associated external guide sequences.
Proceedings of National Academy of Sciences, USA., 99: 3406-3411.
Kruger, K., Grabowski, P.J., Zaug, A.I., Sands, I., Gottschling, D.E., Cech, T.R
(1982) Self-splicing RNA: autoexcision and autocyclization of the ribosomal
RNA intervening sequence of Tetrahymena.Cell, 31(1):147-157.
Kumar, M., Jain, S.K., Pasha, S.T., Chattopadhaya, D., Lal, S. and Rai, A.
(2006) Genomic diversity in the regulatory nef gene sequences in Indian
isolates of HIV type 1: emergence of a distinct subclade and predicted
implications. AIDS Research and Human Retroviruses, 22: 1206-1219.
Kurle, S., Tripathy, S., Jadhav, S., Agnihotri, K. and Paranjape, R (2004) Full
length gag sequences of HIV type 1 subtype C recent seroconverters from
Pune, India. AIDS Research and Human Retroviruses, 20: 1113-1118.
Kurreck, J. (2003). Antisense technologies: Improvement through novel
chemical modifications. European Journal of Biochemistry, 270: 1628-1644.
Kurreck, J., Bieber, B., Jahnel, R and Erdmann, V.A. (2002) Comparative
Study of DNA Enzymes and Ribozymes against the Same Full-length
Messenger RNA of the Vanilloid Receptor Subtype I. Journal of Biological
Chemistry, 277(9): 7099-7107.
Lafontaine, D.A., Norman, D.G. and Lilley, D.M.J. (2002) The global structure
of the VS ribozyme, Embo Journal, 21(10): 2461-2471.
166 I P age
I References
Lakhashe, S., Thakar, M., Godbole, S., Tripathy, S. and Paranjape, R. (2008)
HIV infection in India: epidemiology, molecular epidemiology and
pathogenesis. Journal of Biosciences, 33: 515-525.
Lambowitz, A.M. and Zimmerly, S. (2004) Mobile group II introns. Annual
Review of Genetics, 38: 1-35
Le Gall, S., Heard, J.M., Schwartz, 0.(1997).Analysis of Nef induced MHC-I
endocytosis. Research Virology, 148: 43-47.
Le Rouzic, E. (2007). HIVI Vpr arrests the cell cycle by recruiting
DCAFINprBP, a receptor of the Cul4-DDBI ubiquitin ligase. Cell Cycle,
6:182-188.
Le Rouzic, E., Benichou, S. (2005) The Vpr protein from HIV-l: distinct roles
along the viral life cycle. Retrovirology, 2:11-25.
Levine, B.L. (2006) Gene transfer in humans using a conditionally replicating
lentiviral vector. Proceedings of National Academy of Sciences USA, 103:
17372-17377.
Levy, D.N., Aldrovandi, G.M., Kutsch, 0., Shaw, G.M. (2004) Dynamics of
HIV-l recombination in its natural target cells. Proceedings of National
Academy of Sciences, USA, 101: 4204-4209.
Li, M.J. (2005)Long-term inhibition of HIV-l infection in primary
hematopoietic cells by lentiviral vector delivery of a triple combination of
anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Molecular Therapy 12, 900-909.
Li, Y., Li, X., Stremlau, M., Lee, M. and Sodroski, J. (2006) Removal of arginine
332 allows human TRIM5a to bind human immunodeficiency virus capsids
and to restrict infection. Journal of Virology, 80: 6738-6744.
167 I P age
I References
Li, Y., Liu, Y. and Breaker, RR (2000) Capping DNA with DNA.
Biochemistry, 39: 3106-3114.
Liang, Z., Wei, S., Guan, J., Luo, Y., Gao, J., Zhu, H., Wu, S., Liu, T. (2005)
DNAzyme mediated cleavage of survivin mRNA and inhibition of the growth
of P ANC-1 cells. Journal of Gastroenterology and Hepatology,20 :1595-1602.
Liu, S., Bokinsky, G., Walter, N.G., Zhuang, X.(2007) Dissecting the multistep
reaction pathway of an RNA enzyme by single molecule kinetic
"fingerprinting". Proceedings of National Academy of Sciences USA, 104:
12634-12639.
Lole, KS., Bollinger, RC, Paranjape, RS., Gadkari, D., Kulkarni, S.S., Novak,
N.G. (1999) Full-length human immunodeficiency virus type 1 genomes from
subtype C-infected seroconverters in India, with evidence of intersubtype
recombination. Journal of Virology, 73: 152-160.
Lorsch, J.R, Szostak, J.W. (1994) In vitro evolution of new ribozymes with
polynucleotide kinase activity. Nature, 371: 31-36.
Lumm, J.J., Cohen, Ol, Nie, Z., Weaver, J.G., Gomez, T.s., Yao, X.J., Lynch,
D., Pilon, A.A., Hawley, N, Kim, J.E.(2003). Vpr R77Q is associated with long
term nonprogressive HIV infection and impaired induction of apoptosis.
Journal of Clinical Investigations, 111: 1547-1554.
Lyngstadaas, S.P., Risnes, S., Sproat, B.s., Thrane, p.s. and Prydz, H.P. (1995)
TI A synthetic, chemically modified ribozyme eliminates amelogenin,
the major translation product in developing mouse enamel in vivo. EMBO
Journal, 14(21),5224-5229.
Macejak, D.G., Jensen, KL., Jamison, S.F., Domenico, K, Roberts, E.C,
Chaudhary, N., von Carlowitz, I., Bellon, L., Tong,M.J., Conrad, A., Pavco,
P.A. and Blatt, L.M. (2000) Inhibition of hepatitis C virus (HCV)-RNA-
168 I P age
I References
dependent translation and replication of a chimeric HCV poliovirus using
synthetic stabilized ribozymes. Hepatology, 31(3): 769-776.
Maddon, P.J., Dalgleish, A.G., McDougal, J.5., Clapham, P.R, Weiss, RA.,
Axel, R (1986) The T4 gene encodes the AIDS virus receptor and is expressed
in the immune system and the brain. Cell, 47: 333-348.
Maitra, A., Singh, B., Banu, S., Deshpande, A., Robbins, K, Kalish, M.L.,
Broor, S., Seth, P. (1999) Subtypes of HIV type 1 circulating in India: Partial
envelope sequences. AIDS Research and Human Retroviruses, 15: 941-944.
Malim, M.H., Hauber, J., Le, S.-Y., Maizel, J.V., and Cullen, B.R (1989). The
HIV-l rev trans-activator acts through a structured target sequence to activate
nuclear export of unspliced viral mRNA. Nature, 338: 254-257.
MandaI, D., Jana, S., Bhattacharya, S.K and Chakrabarti, S. (2002) HIV type 1
subtypes circulating in eastern and northeastern regions of India. AIDS
Research and Human Retroviruses, 18: 1219-1227.
Mangasarian, A. and Trono, D. (1997).The multifaceted role of HIV Nef.
Research Virology, 148:30-33.
Marasco, W.A., LaVecchio, J .. and Winkler, A. (1999) Human anti-HIV-l tat
sFv intrabodies for gene therapy of advanced HIV-l-infection and AIDS.
Journal of Immunological Methods, 231: 223-238.
Margottin, F., Bour, S.P., Durand, H., Selig, L., Benichou, S., Richard, V.,
Thomas, D., Strebel, K, Benarous, R(1998) A novel human WD protein, h
beta TrCP, that interacts with HIV-l Vpu connects CD4 to the ER degradation
pathway through an F- box motif. Molecular Cell,l: 565- 574.
Martick, M. and Scott, W.G.(2006) Tertiary Contacts Distant from the Active
Site Prime a Ribozyme for Catalysis, cell,126:309-320.
.169 I P age
I References
Martinez, M.A., Gutierrez, A., Armand-U gon, M., Blanco, J., Parera, M.,
Gomez, J., Clotet, B., Este, J.A.(2002) Suppression of chemokine receptor
expression by RNA interference allows for inhibition of HIV-l replication.
AIDS, 16: 2385-2390.
McCaffrey, A.P., Nakai, H., Pandey, K., Huang, Z., Salazar, F.H., Xu, H.,
Wieland, S.F., Marion,P.L., Kay, M.A.(2003) Inhibition of hepatitis B virus in
mice by RNA interference. Nature Biotechnology, 21: 639-644.
McCutchan, F.E. (2000) Understanding the genetic diversity of HIV-l. AIDS,
14 (SuppI3): S31-44.
McDermott, D.H., Zimmerman, P.A., Guignard, F., Kleeberger, CA., Leitman,
S.F., Murphy, P.M. (1998). CCR5 promoter polymorphism and HIV-l disease
progression. Lancet 352:866-870.
Meister, G., Landthaler,M., Patkaniowska, A., Dorsett, Y., Teng, G., Tuschl, T.
(2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and
siRNAs. Molecular Cell,15: 185-197.
Meli, M., Vergne, J., Maurel, M.C (2003) In vitro selection of adenine
dependent hairpin ribozymes. Journal of Biological Chemistry, 278: 9835-9842 .
. Michael, N.L., Nelson, J.A., KewalRamani, V.N., Chang, G., O'Brien, SJ,
Mascola, J.R, Volsky, B., Louder, M., White, G.C, Littman, D.R, Swanstrom,
R, O'Brien, T.R(1998) Exclusive and persistent use of the entry coreceptor
CXCR4 by human immunodeficiency virus type 1 from a subject homozygous
for CCR5 delta32. Journal of Virology, 72(7): 6040-6047.
Michel, F., Jacquier, A. and Dujon, B. (1982) Comparison of fungal
mitochondrial introns reveals extensive homologies in RNA secondary
structure. Biochemie, 64: 867-81
170 I P age
--------------------
I References
Miedema, F., Meyaard, L., Koot, M., Klein, M.R, Roos, M.T., Groenink, M.
(1994) Changing virus-host interactions in the course of HIV-1 infection.
Immunology Review, 140: 35-72.
Miller, J.W. (2008). Preliminary Results of Gene Therapy for Retinal
Degeneration.The New England journal of Medicine
Millow, KH., Greenough, T.C., Bretttler, D.B., Schindler, M., Wildum, S.,
Sullivan, J.L. (2003) Alterations in HIV-1 LTR promoter activity during AIDS
progression. Virology, 317: 109-118.
Mishra, M., Vetrivel, S., Siddappa, N.B., Ranga, V., Seth, P. (2008) Clade-
specific differences in neurotoxicity of human immunodeficiency virus-1 B
and C Tat of human neurons: significance of dicysteine C30C31 motif. Annual
Neurology, 63(3): 366-376.
Mitchell, A., Dass, C.R, Sun, L-Q., Khachigian, L.M. (2004) Inhibition of
human breast carcinoma proliferation, migration, chemoinvasion and solid
tumor growth by DNAzymes targeting the zinc finger transcription factor
EGR-l. Nucleic Acids Research, 32:3065-3069.
Morellet, N. (2003). NMR structure of the HIV-1 regulatory protein VPR
Journal of Molecular Biology, 327: 215-227.
Morgan, RA. (2005) Preferential survival of CD4+ T lymphocytes engineered
with anti-human immunodeficiency virus (HIV) genes in HIV -infected
individuals. Human Gene Therapy, 16: 1065-1074.
Murrell, M., Khachigian, L., Ward, M.R (2007) The role of c-jun in PDTC-
sensitive flow-dependent restenosis after angioplasty and stenting.
Atherosclerosis, 194(2): 364-71.
171 I P age
I References
Muthumani, K. (2002). HIV-1 Vpr induces apoptosis through caspase 9 in T
cells and peripheral blood mononuclear cells. Journal of Biological Chemistry,
277: 37820-37831.
Neil, S.J., Zang, T., Bieniasz, P.D.(2008) Tetherin inhibits retrovirus release
and is antagonized by HIV -1 Vpu. Nature, 451:425-430.
Neogi, V., Sood, V., Banerjee,S., Ghosh, N., Verma,S., Samrat, 5., Sharma, Y.,
Saxena, A., Husain,S., Ramachandran, V.G., Das, 5., Sreedhar, K.V., Goel, N.,
Wanchu, A. and Banerjea A.C. (2009) Global HIV -1 molecular epidemiology
with special reference to genetic analysis of HIV -1 subtypes circulating in
North India: functional and pathogenic implications of genetic variation.
Indian Journal of Experimental Biology, 47: 424-431.
Neogi, V., Sood, V., Goel, N., Wanchu, A., Banerjea, A.C. (2008) Novel HIV-1
Long Terminal Repeat (LTR) sequences of Subtype B and mosaic intersubtype
BIC Recombinants in North India. Archives of Virology, 153(10): 1961-1966.
Neville, M., Stutz, F., Lee, L., Davis, L.I., and Rosbash, M. (1997).The
importin-beta family member Crm1 p bridges the interaction between Rev and
the nuclear pore complex during nuclear export. Current Biology, 7: 767-775.
Nunamaker, E.A., Zhang, H.Y., Shirasawa, Y., Benoit, J.N., Dean, D.A. (2003)
Electroporation- mediated delivery of catalytic oligodeoxynucleotides for
manipulation of vascular gene expression. American Journal of Physiology,
285:H2240-H2247
Okumura, A., Lu, G., Pitha-Rowe, I., Pitha, P.M.(2006) Innate antiviral
response targets HIV -1 release by the induction of ubiquitin like protein
ISG15. Proceedings of National Academy of Sciences V.s.A. ,103: 1440-1445.
172 I P age
I References
Pan, W.H., Clawson, G.A. (2006) Identifying accessible sites in RNA: the first
step in designing antisense reagents. Current Medicinal Chemistry,13(25):
3083-103.
Pan, W.H., Xin, P., Morrey, J.D. and Clawson, G.A. (2004) A self-processing
ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and
hepatitis B virus. Molecular therapy, 9(4): 596-606.
Paul, M. and Jabbar, M.A.(1997) Phosphorylation of both phospho acceptor
sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu mediated ER
degradation of CD4. Virology, 232: 207-216.
Peeters, M. (2000) Recombinant HIV sequences: Their role in the global
epidemic. In "Human Retroviruses and AIDS: A Compilation and Analysis of
Nucleic Acid and Amino Acid Sequences" (C Kuiken, B. Foley, B. Hahn, B.
Korber, F. McCutchan, P. Marx, J. Mellors, J. Mullins, J. Sidroski, and J.
Wolinsky, Eds.), 54-72. Los Alamos National Laboratory, Los Alamos, New
Mexico.
Perriman, R, Delves, A. and Gerlach, W.L. (1992) Extended target site
specificity for a hammerhead ribozyme, Gene 113, 157-163.
Pfister, E.L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M.,
Landwehrmeyer, B., Vonsattel, J.P., Zamore, P.D., Aronin, N. (2009) Five
siRNAs targeting three SNPs may provide therapy for three-quarters of
Huntington's disease patients. Current Biology, 19(9):774-8.
Piller, S. C, Ewart, G. D., Jans, D. A., Gage, P. W. and Cox, G. B. (1999).The
amino-terminal region of Vpr from human immunodeficiency virus type 1
forms ion channels and kills neurons. Journal of Virology, 73: 4230- 4238.
Platz, J., Grassi, M., Kuhn, A., Kandolf, R, Racchi, G., Farra, R, Dapas, B.,
Pascotto, A., Giansante, C, Fiotti, N., Guarnieri, G., Grassi, G.(2007) Effects of
173 I P age
I References
various promoter derived sequences on the cleavage kinetic of an
hammerhead ribozyme directed against cyclin E1 mRNA.Drug Metab
Lett.1(3):218-225.
Pley, H.W., Flaherty, KM., McKay, D.B. (1994) Three-dimensional structure of
a hammerhead ribozyme. Nature, 372(6501):68-74.
Poller, W., Fechner, H., Kurreck, J., Pauschinger, M., Kiihl, U., Erdmann, V.A.,
Lamers, J.M.J. and Schultheiss, H.-P. (2004) Nucleic acid-based modulation of
cardiac gene expression for the treatment of cardiac diseases. Z. Kard. 93(3),
171-193.
Poon, B., Chang, M.A. and Chen, I.S.Y. (2007). Vpr is required for efficient Nef
expression from unintegrated HIV-1 DNA. Journal of Virology, 81:10515-
10523.
Prody, G.A., Bakos, J.T., Buzayan, J.M., Schneider, I.R, Breuning, G. (1986)
Autolytic processing of dimeric plant virus satellite RNA. Science 231: 1577-
1580.
Purtha, W.E., Coppins, RL., Smalley, M.K and Silverman, S.K (2005) General
deoxyribozyme- catalyzed synthesis of native 3'-5' RNA linkages. Journal of
American Chemical Society, 127: 13124-13125.
Qin, X. F., An, D. S., Chen, I. S. and Baltimore, D. (2003) Inhibiting HIV-1
infection in human T cells by lentiviral-mediated delivery of small interfering
RNA against CCR5. Proceedings of National Academy of Sciences USA, 100:
183-188.
Ramezani, A., Ma, X.Z., Ameli, M., Arora, A., Joshi, S.(2006) Assessment of an
anti-HIV-1 combination gene therapy strategy using the antisense RNA and
multimeric hammerhead ribozymes. Frontier Bioscience,l1: 2940-2948.
174 I P age
I References
Rhodes, T., Wargo, H., Hu, W.5. (2003) High rates of human
immunodeficiency virus type 1 recombination: near-random segregation of
markers one kilobase apart in one round of viral replication. Journal of Virol
2003; 77, 11193-200.
Rodriguez MA,Shen C, Ratner D, Paranjape RS, Kulkarni 55, Chatterjee R.
(2007) Genetic and Functional Characterization of the L TR of HIV -1 Subtypes
A and C circulating in India. AIDS Research and Human Retroviruses, 23:
1428-1433.
Romani, B., Engelbrecht, S. (2009) Human immunodeficiency virus type 1
Vpr: functions and molecular interactions. Journal of General Virology, 90(8):
1795-1805.
Roshal, M. (2001). Apoptosis in AIDS. Apoptosis, 6: 103-116.
Roshal, M., Kim, B., Zhu, Y., Nghiem, P., Planelles, V. (2003) Activation of the
ATR-mediated DNA damage response by the HIV-1 viral protein R. Journal
of Biological Chemistry, 278(28):25879-25886.
Rossi, J. J. (1999). The application of ribozymes to HIV infection. Current
opinion molecular therapy, 1: 316-322.
Rossi, J.J., June, C.H. and Kohn, D.B. (2007) Genetic therapies against HIV.
Nature Biotechnology, 25(12): 1444-1454.
Roth, A., Nahvi,A., Lee,M.(2006) Characteristics of the glmS ribozyme suggest
only structural roles for divalent metal ions. RNA,12: 607-619.
Roumier,T., Vieira, H. L., Castedo, M., Ferri, K. F., Boya, P., Andreau, K.,
Druillennec, 5., Joza, N., Penninger, J. M. (2002). The C-terminal moiety of
HIV -1 Vpr induces cell death via a caspaseindependent mitochondrial
pathway. Cell Death and Differentiation, 9:1212-1219.
175 I P age
I References
Rousseau, C.M., Learn, G.H., Bhattacharya, T., Nickle, D.C., Heckerman, D.,
Chetty, c., Brander, c., Goulder, P.J.R., Walker, B.D., Kiepiela, P., Korber,
B.T., and Mullins, J.I. (2007). Extensive intra subtype recombination in South
African human immunodeficiency virus type 1 subtype C infections. Journal
of Virology, 81: 4492-4500.
Rouzic, E.L., and Benichou, S. (2005). The Vpr protein from HIV-1: distinct
roles along the viral life cycle. Retrovirology, 2: 11.
Rupert, P. B. and Ferre-D'Amare, A. R. (2001) Crystal structure of a hairpin
ribozyme-inhibitor complex with implications for catalysis Nature, 410: 780-
786.
Sahni, A.K., Prasad, V.V. and Seth, P. (2002) Genomic diversity of human
immunodeficiency virus type-1 in India. International Journal of SID.AIDS,
13: 115-118.
Sakai, S., Dimas, J., and Lenardo, J.M. (2006). The Vif and Vpr accessory
proteins independently cause HIV -1 induced T cell cytopathocity and cell
cycle arrest. Proceedings of National Academy of Sciences USA, 103: 3369-
3374.
Salminen MO, Carr JK, Robertson DL, Hegerich P, Gotte D, Koch C. (1997)
Evolution and probable transmission of intersubtype recombinant human
immunodeficiency virus type 1 in a Zambian couple. Journal of Vir'ology, 71:
2647-2655.
Salminen, M. 0., ~arr, J. K., Burke, D. S. & McCutchan, F. E. (1995).
Identification of breakpoints in intergenotypic recombinants of HIV type 1 by
bootscanning. AIDS Research and Human Retroviruses, 11: 1423-1425.
Samson, M., Libert, F., Doranz, B.J., Rucker,J., Liesnard, c., Farber, C.M.,
Saragosti, S., Lapoumeroulie, c., Cognaux, J., Forceille, c., Muyldermans, G.,
176 I P age
I References
Verhofstede, c., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y.J., Smyth,
RJ., Collman, RG., Doms, RW., Vassart, G., Parmentier, M. (1996). Resistance
to HIV -1 infection in Caucasian individuals bearing mutant alleles of the
CCR-5 chemokine receptor gene. Nature, 382:722-725
Santoro, S.W. and Joyce, G.F. (1997) A general purpose RNA-cleaving DNA
enzyme. Proceedings of National Academy of Sciences USA. 94(9): 4262-
4266.
Sawaya, B.E., Khalili, K., Gordon, J., Taube, R, Amini, S.(2000) Cooperative
interaction between HIV-l regulatory proteins Tat and Vpr modulates
transcription of the viral genome. Journal of Biological Chemistry, 275(45):
35209-35214.
Schlosser, K., Gu, J., Lam, J.c., Li, Y. (2008) In vitro selection of small RNA-
cleaving deoxyribozymes that cleave pyrimidine-pyrimidine
junctions. Nucleic Acids Research, 36(14):4768-77.
Schroers, R, Davis, C.M., Wagner, H.J. and Chen, S.Y. (2002)Lentiviral
transduction of human T-Iymphocytes with a RANTES intrakine inhibits
human immunodeficiency virus type 1 infection. Gene Therapy, 9: 889-897.
Schubert, S. and Kurreck, J. (2004) Ribozyme- and Deoxyribozyme-Strategies
for Medical Applications. Current Drug Targets, 5: 667-681.
Schubert, S., Furste, J. P., Werk, D., Grunert, H. P., Zeichhardt, H., Erdmann,
V. A. and Kurreck, J. (2004) Gaining target access for deoxyribozymes.
Journal of Molecular Biology, 339: 355-363.
Schwartz, S.(1991). Expression of human immunodeficiency virus type 1 vif
and vpr mRNAs is Rev-dependent and regulated by splicing. Virology, 183:
677-686.
177 I P age
I References
Sengupta, S., Jana, S., Roy, P., Sarkar, K, Bhattacharya, S.K, Chakrabarti,
S.(2005a) Phylogenetic analysis of the p24-p7 region of the human
immunodeficiency virus type 1 gag gene to determine subtype distribution
among female sex workers in Calcutta. Indian Journal of Clinical
Microbiology, 43: 5787-5791.
Sengupta, S., Khetawat, D., Jana, S., Sarkar, K, Bhattacharya, S.K.,
Chakrabarti, S. (2005b) Polymorphism of HIV-l gag (pI7) gene from female
sex workers in Calcutta, India. Archives of Virology, 150: 2117-2124.
Shankarappa, R, Chatterjee, R, Learn, G.H., Neogi, D., Ding, M., Roy, P.
(2002) Human immunodeficiency virus type 1 env sequences from Calcutta in
eastern India: identification of features that distinguish subtype C sequences
in India from other subtype C sequences. Journal of Virology, 75: 10479-
10487.
Sheehy, A.M., Gaddis, N.C., Choi, J.D., Malim, M.H.(2002) Isolation of a
human gene that inhibits HIV -1 infection and is suppressed by the viral Vif
protein. Nature, 418 (6898): 646-650.
Sherman, M.P., de Noronha, C.M., Pearce, D., Greene, W.C.(2000) Human
immunodeficiency virus type 1 vpr contains two leucine-rich helices that
mediate glucocorticoid receptor coactivation independently of its effects on
G(2) cell cycle arrest. Journal of Virology, 74: 8159-8165.
Shimayama, T., Nishikawa, S. and Taira, K (1995) Generality of the NUX
Rule: Kinetic Analysis of the Results of Systematic Mutations in the
Trinucleotide at the Cleavage Site of Hammerhead Ribozymes, Biochemistry
34: 3649-3654.
178 I P age
I References
Shiota, M., Sano, M., Miyagishi, M. and Taira, K (2004) Ribozymes:
Applications to Functional Analysis and Gene Discovery J. Biochem. 136, 133-
147.
Shriner, D., Rodrigo, A.G., Nickle, D.C., Mullins, J.I.(2004) Pervasive genomic
recombination of HIV -1 in vivo. Genetics, 167: 1573-1583.
Shrivastava, N., Srivastava, A. (2008) RNA interference: an emerging
generation of biologicals. Biotechnol Journal, 3(3):339-353.
Siddappa, N.B., Dash, P.K, Mahadevan, A., Jayasuryan, N., Hu, F., Dice, B.,
Keefe, R, Satish, KS., Satish, B., Sreekanthan, K, Chatterjee, R, Venu, K,
Satishchandra, P., Ravi, V., Shankar, S.K, Shankarappa, Rand Ranga, U.
(2004) Identification of subtype C human immunodeficiency virus type 1 by
subtype-specific PCR and its use in the characterization of viruses circulating
in the southern parts of India. Journal of Clinical Microbiology, 42: 2742-2751.
Siddappa, N.B., Venkatramanan, M., Venkatesh, P., Janki, M.V., Jayasuryan,
N., Desai, A., Ravi, V., Ranga, U.(2006) Transactivation and signaling
functions of Tat are not correlated: biological and immunological
characterization of HIV -1 subtype-C Tat protein. Retrovirology, 3: 53.
Silverman, S.K (2005) In vitro selection, characterization, and application of
deoxyribozymes that cleave RNA. Nucleic Acids Research, 33(19): 6151-6163.
Simoes, E.A., Babu, P.G., John, T.J., Nirmala, S., Solomon, S.,
Lakshminarayana, C.S. and Quinn, T.C. (1987) Evidence for HTLV-III
infection in prostitutes in Tamil Nadu (India). Indian Journal of Medical
Research, 85: 335-338.
Simon-Loriere, E., Galetto, R, Hamoudi, M., Archer, J., Lefeuvre, P. (2009)
Molecular Mechanisms of Recombination Restriction in the Envelope Gene of
the Human Immunodeficiency Virus. PLoS Pathogens, 5(5)
179 I P age
I References
Singh, H.K, Gupta, A., Siberry, G.K, Gupte, N., Sastry, J., Kinikar, A., Shah,
1., Gangakhedkar, RR, Bollinger, RC and Kulkarni, V. (2008)The Indian
pediatric HIV epidemic: a systematic review. Current HIV Research, 6, 419-
432.
Sioud, M., and Leirdal, M. (2002). Gene silencing in mammalian cells by
performed RNA duplexes. Biochemical Biophysical Research
Communications, 295: 744-748.
Slim, G. and Gait, M.J. (1991) Configurationally defined phosphothioate
containing oligoribonucleotide in the study of the mechanism of cleavage of
hammerhead ribozymes. Nucleic Acid Research,19: 1183-1188.
Song, E., Zhu, P., Lee, S.K, Chowdhury, D., Kussman, S., Dykxhoorn, D.M.,
Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A., Lieberman,
J.(2005) Antibody mediated in vivo delivery of small interfering RNAs via cell
surface receptors. Nature biotechnology, 23: 709-717.
Sood, V., Gupta, N., Bano, A. S. and Banerjea, A.C (2007)DNA-Enzyme
Mediated Cleavage of Human Immunodeficiency Virus Type 1 Gag RNA Is
Significantly Augmented by Antisense-DNA Molecules Targeted to
Hybridize Close to the Cleavage Site. Oligonucleotides, 17(1) : 113-121.
Sood, V., Ranjan, R, Banerjea, A.C (2008) Functional analysis of HIV-1
subtypes Band C HIV -1 Tat exons and RGD/QGD motifs with respect to Tat
mediated transactivation and apoptosis. AIDS, 22(13): 1683-1685.
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K, Constien, R, Donoghue,
M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V.,
Lavine, G., Pandey, RK, Racie, T., Rajeev, KG. (2004) Therapeutic silencing
of an endogenous gene by systemic administration of modified siRNAs.
Nature, 432: 173-178.
180 I P age
I References
Spina, CA., Kwoh, T.J., Chowers, M.Y., Guatelli, J.C, and Richman, D.D.
(1994). The importance of nef in the induction of human immunodeficiency
virus type 1 replication from primary quiescent CD4 lymphocytes. Journal of
Experimental Medicine, 179: 115-123.
Sreedhara, A., Li,Y. and Breaker,RR (2004) Ligating DNA with DNA. Journal
of American Chemical Society, 126: 3454-3460.
Srinivasan, A., Ayyavoo, V., Mahalingam, S., Kannan, A., Boyd, A., Datta, D.,
Kalyanaraman, V. S., Cristillo, A., Collman, R G. (2008). A comprehensive
analysis of the naturally occurring polymorphisms in HIV -1 Vpr: potential
impact on CTL epitopes. Virology Journal, 5: 99-116.
Stark, B. C, Kole, R, Bowman, E. J., and Altman, S. (1978) Ribonuclease P: an
Enzyme with an Essential RNA Component. Proceedings of National
Academy of Sciences, U. S. A. 75: 3717-3721.
Strebel, K., Klimkait, T., Martin, M.A. (1988) A novel gene of HIV-l, vpu, and
its 16 KDa product. Science, 241:1221-1223.
Sun, L-Q., Cairns, M.J., Gerlach, W.L., Witherington, C, Wang, L., King, A.
(1999) Suppression of smooth muscle cell proliferation by a c-myc RNA
cleaving deoxyribozyme. Journal of Biological Chemistry, 274: 17236-17241.
Surabhi, RM. and Gaynor, RB.(2002) RNA interference directed against viral
and cellular targets inhibits human immunodeficiency Virus Type 1
replication. Journal of Virology, 76: 12963-12973.
Suryavanshi, G.W., Dixit, N.M. (2007) Emergence of recombinant forms of
HIV: dynamics and scaling. PLoS Computational Biology, 3: e205.
Suzuki, T., Yamamoto, N., Nonaka, M., Hashimoto, Y., Matsuda, G.,
Takeshima, S. N., Matsuyama, M., Igarashi, T., Miura, T. (2009). Inhibition of
----_._ ..... 181 I P age
I References
human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr
importin a interactions as a novel HIV-1 therapy. Biochemical Biophysical
Research Communications, 380: 838-843.
Talini, G., Gallori, E., Maurel, M.C(2009) Natural and unnatural ribozymes:
back to the primordial RNA world. Research in microbiology,160 (7): 457-465.
Taylor, N.R, Kaplan, B.E., Swiderski, P., Li,H., Rossi, J.J.(1992) Chimeric
DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency
and increased stability in vivo.Nucleic Acids Res.20(17):4559-65.
Templeton, A.R, Kramer, M.G., Jarvis, J., Kowalski, J., Gange, S., Michael F
Schneider, M.F. Shao, Q., Zhang, G.W., Yeh, M.F., Tsai, H.L., Zhang, H.and
Markham, RB. (2009) Multiple-infection and recombination in HIV -1 within a
longitudinal cohort of women. Retrovirology, 6:54
Thotala, D., Schafer, E.A., Majumder, B., Janket, M.L., Wagner, M., Srinivasan,
A. (2004) Structure-functional analysis of human immunodeficiency virus
type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation
and virus replication. Virology, 328: 89-100.
Tripathy, S.P., Kulkarni, S.5., Jadhav, S.D., Agnihotri, KD., Jere, A.J., Kurle,
S.N., Bhattacharya, S.K, Singh, K, Tripathy, S.P. and Paranjape, RS. (2005)
Subtype B and Subtype C HIV Type 1 Recombinants in the Northeastern State
of Manipur, India. AIDS Research and Human Retroviruses, 21, 152-157.
Tristem, M.(1998). Complex evolutionary history of primate lentiviral vpr
genes. Virology, 240: 232-237.
Trkola, A., Dragic, T., Arthos, J., Binley, J.M., Olson, W.C, Allaway, G.P.
(1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its
co-receptor CCR-S. Nature, 384:184-187.
182 I P age
I References
Tungaturthi, P.K. (2003). Role of HIV-1 Vpr in AIDS pathogenesis: relevance
and implications of intravirion, intracellular and free Vpr. Biomedical
Pharmacotherapy, 57: 20-24.
Uhlenbeck, O.C (1987) A small catalytic oligoribonudeotide. Nature,. 328:
596-600.
UNAIDS Report of the global AIDS epidemic. 2008. http://www.unaids.org
len IKnowledgecentre/HIVData/GlobaIReport/2008/2008_Global_report. asp.
accessed in September 2008
Unwalla, H., Banerjea, A.C (2001) Novel mono- and di-DNA-enzymes
targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene
expression. Antiviral Research, 51:127-139.
Unwalla, H.J., Li, H., Li, S.Y., Abad, D., Rossi, J.J .. (2008) Use of a U16
snoRNA-containing ribozyme library to identify ribozyme targets in HIV-
l.Mol Ther. 16(6):1113-1119.
Usman, N. and Blatt, L.M. (2000) Nuclease-resistant synthetic ribozymes:
developing a new class of therapeutics Journal of Clinical Investigation,
106(10): 1197-1202.
Vanitharani, R., Mahalingam, 5., Rafaeli, Y., Singh, S.P., Srinivasan, A.,
Weiner, D.B., Ayyavoo, V.(2001) HIV-1 Vpr transactivates LTR-directed
expression through sequences present within -278 to -176 and increases virus
replication in vitro. Virology, 289: 334-342.
Vodicka, M. A., Goh, W. C, Li,W., Rogel, M. E., Bartz, S. R., Schweickart, V.
L., Raport, C J., and Emerman, M. (1997) Indicator cell lines for detection of
primary strains of human and simian immunodeficiency viruses. Virology,
233: 193-198.
183 I P age
-----------------
I References
Wang, D.Y., Sen, D. (2001) A novel mode of regulation of an RNA-cleaving
DNAzyme by effectors that bind to both enzyme and substrate. Journal of
Molecular Biology, 310: 723-34.
Wang, L., Mukherjee, S., Jia, F., Narayan, O. & Zhao, L. J. (1995). Interaction of
virion protein Vpr of human immunodeficiency virus type 1 with cellular
transcription factor Sp 1 and trans-activation of viral long terminal repeat.
Journal of Biological Chemistry, 270: 25564-25569.
Wang, W., Billen, L.P. and Li, Y. (2002) Sequence diversity, metal specificity,
and catalytic proficiency of metal-dependent phosphorylating DNA enzymes.
Chemical Biology, 9: 507-517.
Weiss, R, Teich, N., Varmus, H. And Coffin, J., eds (1984) RNA tumor
viruses. Vol.1 & 2. Cold spring Harbour: Cold spring harbour lab.1292 pp.,
2344 pp 2nd edition.
Weiss, RA.(200l) Gulliver's travel in HIVland. Nature, 410: 963-967.
Weissenhoni., W., Dessen, A., Harrison, S.C, Skehel, J.J., Wiley, D.C (1997)
Atomic structure of the ectodomain from HIV-1 gp41. Nature, 387:426-430.
Win, M.N., Smolke, CD. (2007) A modular and extensible RNA-based gene
regulatory platform for engineering cellular function.Proc Natl Acad Sci USA
104:14283-14288.
Winkler, C, Modi, W., Smith, M.W., Nelson, G.W., Wu, X., Carrington, M.,
Dean, M., Honjo, T., Tashiro, K., Yabe, D., Buchbinder, S., Vittinghoff, E.,
Goedert, J.J., O'Brien, T.R, Jacobson, L.P., Detels, R, Donfield, S., Willoughby,
A., Gomperts, E., Vlahov, D., Phair, J., O'Brien, S.J. (1998). Genetic restriction
of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science, 279: 389-
393.
184 I P age
I References
Woffendin, c., Ranga, V., Yang, Z., Xu, L. and Nabel, G.J. (1996) Expression of
a protective gene-prolongs survival of T cells in human immunodeficiency
virus-infected patients. Proceedings of National Academy of Sciences, VSA,
93: 2889-2894.
Wong-Staal, F., Poeschla, E.M. and Looney, D.J.(1998) A controlled, phase 1
clinical trial to evaluate the safety and effects in HIV -1 infected humans of
autologous lymphocytes transduced with a ribozyme that cleaves HIV-l
RNA. Human Gene Therapy, 9: 2407-2425.
Wu, Y., McMahon, R, Rossi, J.J., Forman, S.J., Snyder, D.5. (1999) Inhibition of
bcr-abl oncogene by novel deoxyribozymes (DNAzymes). Human Gene
Therapy, 10:2847 -2857.
Xiang, G., Seki, T., Schuster, M.D., Witkowski, P., Boyle, Al, See, F., Martens,
T.P., Kocher, A., Sondermeijer, H., Krum, H., Itescu, S. (2005) Catalytic
degradation of vitamin D up-regulated protein 1 mRNA enhances
cardiomyocyte survival and prevents left ventricular remodeling after
myocardial ischemia. Journal of Biological Chemistry, 280: 39394-39402.
Yamamoto, K., Morishita, R, Tomita, N., Shimozato, T., Nakagami, H.,
Kikuchi, A., Aoki, M., Higaki, J., Kaneda, Y. and Ogihara, T. (2000) Ribozyme
oligonucleotide against transforming growth factor B inhibited neonatal
formation after vascular injury in rat model: potential application of
Ribozyme strategy to treat cardiovascular disease. Circulation, 102(11), 1308-
1314.
Young, K.J., Gill, F. and Grasby, J.A. (1997) Metal ions playa passive role in
the hairpin ribozyme catalysed reaction, Nucliec Acid research, 25(19): 3760-
3766.
185 I P age
I References
Yu, X., Yu, Y., Liu, B., Luo, K., Kong,W., Mao, P. & Yu, X. F. (2003). Induction
of APOBEC3G ubiquitination and degradation by an HIV -1 Vif-CuI5-SCF
complex. Science, 302: 1056-1060.
Zander, K. (2003). Cyclophilin A interacts with HIV-1 Vpr and is required for
its functional expression. Journal of Biological Chemistry, 278: 43202-43213.
Zhang, G., Dass, C.R, Sumithran, E., Di Girolimo, N.R, Sun, L-Q.,
Khachigian, L.M. (2004) Effect of deoxyribozymes targeting c-Jun on solid
tumor growth and angiogenesis in rodents. Journal of National Cancer
Institute, 96: 683-696.
Zhang, G., Luo, X., Sumithran, E., Pua, V.S.c., Barnetson, RS., Halliday, G.M.,
Khachigian, L.M.(2006) Squamous cell carcinoma growth in mice and in
culture is regulated by c-Jun and its control of matrix metalloproteinase- 2
and -9 expression. Oncogene, 25: 7260-7266.
Zhang, H., Kolb, F.A., Jaskiewicz, L., Westhof, E., Filipowicz, W. (2004) Single
processing center models for human Dicer and bacterial RNase III. Cell, 118:
57-68.
Zhang, L., Gasper, W.J., Stass, S.A., Ioffe, O.B., Davis, M.A., Mixson, A.J.
(2002) Angiogenic inhibition mediated by a DNAzyme that targets vascular
endothelial growth factor receptor 2. Cancer Research, 62: 5463-5469.
Zheng,Y.H., Lovsin, N. and Peterlin, B. M. (2005). "Newly identified host
factors modulate HIV replication". Immunology Letter, 97 (2): 225-234.
Zhou, B.B., Elledge, S.J.(2000). The DNA damage response: putting
checkpoints in perspective. Nature, 408: 433-439.
186 I P age
I References
Zhou, J., Li, H., Li, 5., Zaia, J., Rossi, J.J. (2008) Novel dual inhibitory function
aptamer-siRNA delivery system for HIV-1 therapy. Molecular
Therapy,16(8):1481-1489.
Zimmerman, B.S., Chen, J., Andersen, J.L., Ardon, 0., Dehart, J.L., Blackett, J.,
Choudhary, S.K., Camerini, D., Nghiem, P., Planelles, V.(2004) Human
immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and
Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.
Molecular Cell Biology, 24(21): 9286-9294.
Zinnen, S.P., Domenico, K., Wilson, M., Dickinson, B.A., Beaudry, A., Mokler,
v., Daniher, A.T., Burgin, A. and Beigelman, L. (2002) Selection, design, and
characterization of a new potentially therapeutic ribozyme.RNA, 8(2): 214-228.
187 I P age